List of Excipients in Branded Drug FYAVOLV

Generic Drugs Containing FYAVOLV

Company	Ingredient	NDC	Excipient
Lupin Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	68180-827	CALCIUM STEARATE
Lupin Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	68180-827	CELLULOSE, MICROCRYSTALLINE
Lupin Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	68180-827	HYPROMELLOSES
Lupin Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	68180-827	LACTOSE MONOHYDRATE
Lupin Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	68180-827	POLYETHYLENE GLYCOL 400

What are the Most Frequently-Used Excipients in FYAVOLV?

# Of NDCs	Excipient
1	CALCIUM STEARATE
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSES
1	LACTOSE MONOHYDRATE
1	POLYETHYLENE GLYCOL 400

FYAVOLV Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

FYAVOLV is an oral menopausal hormone therapy containing norethindrone acetate and ethinyl estradiol. Its commercial opportunity is primarily generic lifecycle management, differentiated tolerability, supply reliability, and alternative dosage-form development. The active ingredients are old, the product faces generic competition, and no meaningful current exclusivity moat is apparent from the public FDA record. Excipients can still support product differentiation through lactose reduction, dissolution control, packaging stability, and patient-specific formulations. [1][2]

What is FYAVOLV and how is it regulated?

FYAVOLV is a prescription combination estrogen-progestin product indicated for moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause. It is supplied in two strengths:

Product	Norethindrone acetate	Ethinyl estradiol
FYAVOLV low strength	0.5 mg	2.5 mcg
FYAVOLV high strength	1 mg	5 mcg

The product is administered orally, typically as a continuous daily regimen. The drug combines an estrogen component with a progestin component to reduce endometrial hyperplasia risk associated with unopposed estrogen therapy. [1]

The relevant U.S. regulatory pathway is an abbreviated new drug application for conventional immediate-release generic tablets. A reformulated product with a materially different release profile, dosage form, or clinical positioning could require a 505(b)(2) application rather than a standard ANDA. [3]

What excipients are used in FYAVOLV tablets?

FYAVOLV uses conventional tablet excipients. The FDA labeling and product information identify inactive ingredients that support tablet compression, coating, appearance, and stability. The precise excipient profile can vary by strength and manufacturing presentation, so the approved label should control any regulatory or formulation assessment. [1]

The functional architecture is expected to include:

Excipient function	Commercial purpose
Diluent, such as lactose	Provides tablet bulk at a very low active-drug load
Starch or pregelatinized starch	Supports granulation, disintegration, and tablet integrity
Magnesium stearate	Provides lubrication during compression
Film-coating polymers	Improve swallowability, protect the tablet, and control appearance
Opacifiers and colorants	Support strength differentiation and product identification
Coating plasticizers	Improve film flexibility and reduce coating defects

The low dose of ethinyl estradiol is the main formulation challenge. At 2.5 or 5 micrograms per tablet, content uniformity and blend homogeneity are more important than excipient cost. A low-cost formula that produces segregation or assay variability creates disproportionate manufacturing risk.

What excipient attributes matter most for FYAVOLV?

The highest-value excipient attributes are:

1. Consistent particle-size distribution.
2. Low moisture variability.
3. Reliable flow and blend uniformity.
4. Compatibility with both steroid hormones.
5. Minimal impact on dissolution.
6. Strong supply continuity.
7. Acceptability for chronic use in older patients.

Excipient selection should prioritize process capability over novelty. A novel excipient is unlikely to create sufficient commercial value in a conventional immediate-release hormone tablet to justify additional regulatory and toxicological work.

Which excipient strategies can differentiate a generic FYAVOLV product?

Lactose-free or reduced-lactose formulations

A lactose-free version could target patients with lactose intolerance or pharmacies seeking broader excipient options. Suitable replacement systems may include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or combinations of these materials.

The principal technical risks are altered tablet hardness, disintegration, mouthfeel, and dissolution. A lactose-free formulation would need to demonstrate pharmaceutical equivalence and bioequivalence if submitted through an ANDA. The commercial opportunity is niche rather than mass-market because most patients tolerate the small amount of lactose used in tablets.

Low-moisture formulations

Moisture control can improve assay stability and reduce degradation during long-term storage. A low-moisture excipient system may be useful when the selected steroid combination shows sensitivity to humidity or when the manufacturer wants to extend packaging flexibility.

Potential approaches include:

• Low-water-activity fillers.
• High-barrier blister packaging.
• Desiccant-containing bottles.
• Moisture-protective film coatings.
• Tighter granulation and drying controls.

Packaging often offers a more efficient stability solution than changing the core excipient system. For a mature oral tablet, a high-barrier blister may create more value than a complex reformulation.

Direct-compression formulations

Direct compression can reduce manufacturing steps and lower conversion cost. It is attractive for a generic manufacturer seeking a low-cost supply model.

The main barriers are low-dose content uniformity, segregation during transfer, and lubricant sensitivity. A robust direct-compression process would require careful control of:

• Premix dilution.
• Geometric blending.
• Carrier particle size.
• Hopper residence time.
• Compression speed.
• Blend hold time.

The commercial benefit is strongest where production volume is high and the manufacturer can use a common platform for several hormone products.

Modified-release or lower-dose formulations

A modified-release product could seek smoother hormone exposure or a different dosing profile. This would be a lifecycle-management opportunity rather than a conventional generic opportunity.

The regulatory burden would be materially higher. The sponsor could need comparative pharmacokinetic studies, additional dissolution work, and potentially clinical data supporting the modified regimen. The market may also be limited because physicians already have multiple hormone therapy delivery options, including patches, gels, creams, rings, and other oral products.

Alternative coating systems

A film-coating change is one of the lower-risk differentiation strategies. Benefits may include:

• Improved swallowing.
• Better color coding between strengths.
• Lower friability.
• Reduced moisture ingress.
• Removal of certain dyes.
• Improved appearance and product identification.

The coating should not materially alter dissolution unless the sponsor is deliberately developing a modified-release product.

What patents protect FYAVOLV and its formulation?

The commercial patent position for FYAVOLV is weak compared with recently approved branded drugs. Norethindrone acetate and ethinyl estradiol are long-established molecules, and any basic compound patents would have expired long before the current generic market.

Public FDA Orange Book records should be reviewed under both the brand name and the active-ingredient combination for current listed patents, exclusivity codes, and discontinued-product status. The Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved drug products. [2]

The practical patent categories are:

Patent category	Likely commercial relevance
Basic composition-of-matter patents	Expired
Original combination-product patents	Expired or commercially immaterial
Conventional immediate-release tablet patents	Limited
Excipient-specific patents	Unlikely to block standard generic entry
Method-of-use patents	Potentially narrow and difficult to enforce against routine substitution
Packaging patents	Possible, but generally avoidable
Modified-release formulation patents	Potentially relevant to a new lifecycle product

A company developing a conventional generic should focus on freedom to operate around manufacturing processes, supplier technology, and any later-developed formulation patents rather than expecting a durable FYAVOLV product patent position.

When did FYAVOLV lose exclusivity and when can generic products enter?

FYAVOLV does not have the exclusivity profile of a recently approved branded medicine. The active ingredients and therapeutic combination have been commercially available for many years, and generic norethindrone acetate/ethinyl estradiol tablets are marketed in the United States.

Generic entry is therefore governed mainly by:

• ANDA approval.
• Demonstration of pharmaceutical equivalence.
• Bioequivalence.
• Current manufacturing compliance.
• Absence of blocking listed patents.
• Commercial decisions by generic manufacturers.

There is no biosimilar pathway for FYAVOLV. Biosimilars apply to biological products, while FYAVOLV is a chemically synthesized small-molecule tablet. [3]

What is the Orange Book status of FYAVOLV?

The Orange Book should be checked for:

1. The FYAVOLV brand listing.
2. The active ingredients and strengths.
3. Any listed patents.
4. Pediatric-exclusivity codes.
5. Product-marketing status.
6. Approved generic equivalents.

For an old combination tablet, the expected regulatory profile is a mature market with no meaningful remaining new-drug exclusivity and possible discontinuation or inactive marketing status for the branded product. The presence of a brand listing does not itself establish a current commercial barrier. The relevant question is whether the FDA lists unexpired patents or exclusivity that would delay approval or launch of an ANDA. [2]

Which companies are challenging FYAVOLV, and what Paragraph IV risks exist?

Generic competition is already the principal challenge to FYAVOLV. A new applicant would ordinarily pursue an ANDA and certify against Orange Book-listed patents. If an unexpired patent were listed, the applicant could submit a Paragraph IV certification stating that the patent is invalid, unenforceable, or not infringed. [4]

For a mature FYAVOLV product, the commercial importance of Paragraph IV litigation is likely lower than for a blockbuster drug because:

• The molecule is old.
• The dosage form is conventional.
• Multiple generic manufacturers may already supply the market.
• The brand may have limited current sales.
• Any litigation would likely concern a narrow formulation or method patent.

A generic manufacturer should still conduct a patent search covering the combination, strengths, tablet composition, manufacturing process, and therapeutic use. Later-filed patents can create litigation exposure even when the original product patents have expired.

What manufacturing and intellectual-property barriers affect FYAVOLV generics?

The main barriers are operational rather than patent-based.

Low-dose uniformity

Ethinyl estradiol is present at microgram levels. Blend uniformity, sampling design, and segregation control are critical. A manufacturer may need a premix strategy or validated high-shear blending process to achieve reliable content uniformity.

Steroid handling

Hormonal active ingredients require controlled handling, cleaning validation, and cross-contamination controls. Dedicated equipment may not always be necessary, but the facility must demonstrate adequate containment and cleaning performance.

Dissolution equivalence

Excipients that increase tablet hardness or reduce wetting can affect dissolution. Changes to filler grade, starch type, lubricant concentration, or coating weight should be assessed against the reference product.

Supplier continuity

A single-source colorant, coating polymer, or specialty excipient can create avoidable supply risk. A dual-source strategy is commercially valuable, particularly for products with low selling prices and limited inventory buffers.

Analytical capability

Assay and content-uniformity methods must distinguish and quantify both steroid components at low concentrations. Analytical method robustness can become a more significant barrier than tablet compression itself.

How strong is the FYAVOLV patent estate?

The estate is commercially weak for conventional immediate-release generic competition.

Factor	Assessment
Active-ingredient protection	Expired
Combination-product protection	Mature and unlikely to block routine entry
Conventional tablet protection	Low
Excipient differentiation	Available, but generally nonexclusive
Method-of-use protection	Potentially narrow
Modified-release opportunity	Moderate, with higher regulatory cost
Litigation risk	Low to moderate, depending on current listed patents
Generic substitution risk	High

The most defensible intellectual property would likely arise from a genuinely differentiated delivery system, a new pharmacokinetic profile, a technically difficult manufacturing process, or a formulation that solves a documented stability or tolerability problem. A simple substitution of lactose with microcrystalline cellulose is unlikely to create a durable patent position by itself.

What commercial opportunities exist for FYAVOLV excipient innovation?

1. Private-label and authorized-generic supply

The largest near-term opportunity is reliable, low-cost supply of equivalent tablets. Retail, mail-order, and managed-care channels can favor suppliers that offer stable availability, multiple strengths, and competitive acquisition cost.

2. Patient-specific excipient positioning

A lactose-free, dye-reduced, or low-allergen version could support pharmacy and specialty-distribution channels. The opportunity is more likely to come from formulary preference and patient retention than from a large price premium.

3. Calendar-pack or adherence packaging

Continuous hormone therapy can benefit from clear daily-use packaging. A calendar blister, strength-coded pack, or adherence-oriented package could differentiate the product without changing the tablet formulation.

Packaging patents may be available, but they should be designed around practical usability and manufacturing efficiency rather than exclusivity alone.

4. Multi-product manufacturing platforms

A manufacturer with an existing steroid-tablet platform can reduce cost through common excipients, shared coating systems, and standardized analytical methods. This approach may be more valuable than developing an isolated FYAVOLV formulation.

5. Alternative dosage forms

A softgel, orally disintegrating tablet, or modified-release tablet could target swallowing difficulty or differentiated hormone exposure. These products would face stronger regulatory and clinical requirements, and their commercial value would depend on evidence of a meaningful patient benefit.

6. International commercialization

Geographic opportunity depends on local registration status, reference-product availability, trademark rights, and local patent records. U.S. freedom to operate does not establish freedom to operate in Europe, Canada, Japan, Latin America, or emerging markets. Hormone therapy products also face differing local requirements for labeling, risk communication, and substitution.

How does FYAVOLV compare with other menopausal hormone therapies?

Product category	Excipient opportunity	Commercial position
FYAVOLV oral tablet	High process and supply-chain leverage; limited patent value	Mature generic market
Estradiol-only tablet	Similar low-dose uniformity issues	Broad generic competition
Transdermal estradiol patch	Adhesive, release membrane, and wear-time IP	Higher technical barriers
Vaginal estrogen cream	Preservative, emulsion, and applicator differentiation	Formulation-sensitive
Vaginal ring	Polymer and controlled-release technology	More defensible formulation IP
Oral micronized progesterone	Softgel and dissolution optimization	Established generic competition
Combined transdermal products	Adhesive and delivery-system patents	Higher development cost

FYAVOLV is easier to manufacture than a transdermal system or vaginal ring, but that simplicity reduces defensibility. The strongest commercial strategy is usually cost, availability, tolerability, and packaging rather than a high-margin proprietary excipient platform.

What revenue exposure does FYAVOLV create for manufacturers?

Revenue exposure is concentrated in unit volume and supply continuity rather than premium pricing. A manufacturer can protect gross margin through:

• Efficient direct compression.
• High-yield coating.
• Dual-source excipients.
• Minimal SKU complexity.
• Automated content-uniformity controls.
• High-throughput blister or bottle packaging.
• Reduced product complaints and recalls.

The two strengths create manageable SKU complexity, but each must maintain reliable dose proportionality, appearance differentiation, and inventory availability. A stockout can shift prescriptions to competing generics with limited recovery potential.

What generic launch scenarios exist for FYAVOLV?

Base case: conventional ANDA competition

A manufacturer launches an immediate-release tablet matching the reference product. The main investment is formulation development, bioequivalence, analytical validation, and commercial-scale manufacturing.

Value case: excipient-differentiated generic

A lactose-free, dye-reduced, or improved-stability formulation gains pharmacy adoption. The product remains an ANDA if it meets equivalence requirements.

Premium case: reformulated lifecycle product

A sponsor develops a modified-release or alternative dosage form under a 505(b)(2) strategy. This creates more differentiation but requires a larger clinical and regulatory investment.

Risk case: supply disruption

An excipient shortage, steroid-containment issue, or analytical failure creates temporary market scarcity. Manufacturers with qualified alternate suppliers and validated backup processes can capture displaced demand.

Key Takeaways

• FYAVOLV contains norethindrone acetate and ethinyl estradiol in two oral tablet strengths.
• The commercial opportunity is generic and lifecycle-focused, not based on active-ingredient exclusivity.
• Excipients matter most for low-dose content uniformity, dissolution, stability, and manufacturing cost.
• Lactose-free, dye-reduced, low-moisture, and packaging-differentiated products are the most practical opportunities.
• A conventional excipient change is unlikely to create strong standalone patent protection.
• Modified-release and alternative dosage forms offer greater differentiation but require higher regulatory investment.
• There is no biosimilar pathway because FYAVOLV is a small-molecule tablet.
• Current Orange Book patents, marketing status, and generic-equivalence listings should control any launch or litigation assessment.
• Manufacturing reliability and supply continuity are likely to create more value than formulation novelty.

FAQs About FYAVOLV Excipient and Commercial Strategy

Can a lactose-free FYAVOLV generic be approved through an ANDA?

Yes. A lactose-free formulation can use the ANDA pathway if it remains pharmaceutically equivalent and demonstrates bioequivalence to the reference product. The formulation must also meet quality, dissolution, stability, and manufacturing requirements.

Does FYAVOLV have biosimilar competition?

No. FYAVOLV is a chemically synthesized small-molecule combination tablet. Competitors use the generic-drug pathway, not the biosimilar pathway.

Can an excipient change create patent protection for a FYAVOLV generic?

Possibly, but only if the formulation provides a non-obvious technical effect and satisfies patentability requirements. A routine filler or lubricant substitution generally offers weak patent protection.

Is a modified-release FYAVOLV product commercially attractive?

It could be attractive if it provides a clinically meaningful dosing or tolerability benefit. The opportunity carries substantially higher development, bioequivalence, and regulatory costs than a conventional generic.

What is the most defensible commercial strategy for FYAVOLV?

The strongest practical strategy is a reliable, cost-efficient tablet platform with robust low-dose uniformity, dual-source excipients, moisture-protective packaging, and targeted differentiation such as lactose reduction or improved adherence packaging.

References

1. U.S. National Library of Medicine. (n.d.). Fyavolv: Norethindrone acetate and ethinyl estradiol tablet labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of abbreviated applications. https://www.fda.gov/